December 4, 2023

Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

23-CNR-4221120 ASH 2023 Graphics-CQD

As the premier event for hematology, the American Society of Hematology annual meeting presents more than 7,000 abstracts about cutting-edge science in the field. This year’s event in San Diego, California is being held in person and virtually. Cleveland Clinic Cancer Institute leadership are calling out the below ten abstracts to watch for during the event.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

  1. Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Abstract #91, being presented at 9:30AM on 12/9/23.

  1. Decreased Survival Among Patients with Indolent Systemic Mastocytosis: A Population-Level Retrospective Cohort Analysis Using Healthcare Claims Dataset

Abstract #75, being presented at 10:00AM on 12/9/23.

  1. A Syngeneic Murine Model of Antiphospholipid Syndrome (APS) Recapitulates Aspects of Human APS

Abstract #1190, being presented at 5:30-7:30PM on 12/9/23

  1. A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Abstract #2097, being presented at 5:30-7:30PM on 12/9/23

  1. Improving Patient Access and Provider Availability in Classical Hematology: The Development of an Advanced Practice Provider Led Virtual Anemia Consult Clinic

Abstract #2298, being presented at 5:30-7:30PM on 12/9/23

  1. Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen (CAR) T-Cell Therapy

Abstract #308, being presented at 4:15PM on 12/9/23

  1. Risk of Therapy-Related Acute Myeloid Leukemia in Adolescent and Young Adults Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Abstract #377, being presented at 5:00PM on 12/9/23

  1. Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Abstract #540, being presented at 1:15PM on 12/10/23

  1. Final Results of a Phase 1/2 Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma

Abstract #3087, being presented at being presented at 6:00-8:00PM on 12/10/23

  1. A Phase 2 Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Abstract #775, being presented at 10:30AM on 12/11/23

Related Articles

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

23-CNR-3741790-CQD-Hero-650×450 cell mobilization
April 24, 2023
Plerixafor is Effective for Hematopoietic Progenitor Cell Mobilization in Patients with AL Amyloidosis

On-demand stem cell mobilizer is an effective salvage strategy

CAR T-cell therapy
April 5, 2023
Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms

April 27, 2022
Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study

Novel three-drug regimen used to manage life-threatening developments

March 23, 2022
Experimental Drug Shows Promise for Alleviating Myelofibrosis-Associated Anemia

Momelotinib, a new JAK inhibitor, inches closer to market approval

Mukherjee CQD 654×450
March 8, 2022
Novel Algorithm Highlights the Burden of Idiopathic Multicentric Castleman Disease

Claims data reveal disorder is often overlooked and undertreated